One Sample, One Date and 2:18:31 — Peres Jepchirchir's EPO Case, Read as a Ledger Entry

First, the date. 30 August 2026, Sydney Marathon, women's race — Peres Jepchirchir, 33, Kenya, 2 hours 18 minutes 31 seconds. Second place went to her compatriot Irene Chepet Cheptai, more than three minutes back. Sydney became the seventh World Marathon Major in 2026, and this was its first women's winner who already had four of the other six on her card. Now the second date. It falls before 30 August, in Kenya, and it belongs to an out-of-competition sample. The Athletics Integrity Unit's notice says that sample returned an adverse finding for erythropoietin — EPO — and what followed is the dullest part of the machinery: a provisional suspension. Let me put the caveat where it belongs, because this is where the coverage usually slips. A provisional suspension is not a finding of guilt. There is a B sample, there is a hearing, and no decision has been made. I keep ledgers on injuries, not on doping. But both kinds of paper are loudest in the same column — the date. In an injury file I ask how much the weekly load rose and in which week; in a doping file I ask when the sample was taken, when the race was run, and what happened in the days between. In Jepchirchir's case that sequence is the whole story: sample first, victory second. Much of the reporting has it the other way round, victory first and sample after, and that inversion erases the one hard fact of the case. I opened the women's marathon ledger and EPO was already on the page twice — once in 2026, once in 2026, both against champions of Boston and of the Olympic Games. That is my first question and my last one: not a new event, a new page. What gets written on it is the only thing worth arguing about. The record itself needs no introduction. In 2026 she ran 1:05:06 in Ras Al Khaimah for the half marathon world record. In 2026 she broke it three times, including the women's-only mark in Prague and again at the World Half Marathon Championships in Gdynia. She was not merely a marathoner; she was the definition of the speed that precedes the marathon. Then 7 August 2026, Sapporo, because the Tokyo Olympic marathon had been moved north for the heat. She won in 2:27:20, with Brigid Kosgei second and Molly Seidel third. I watched that race at four in the morning, and what stayed with me was not the clock but her face after the fifth kilometre — a woman who had already done the arithmetic of who would break and when. After that the ledger fills in: New York 2026 in 2:22:39, Boston 2026 in 2:21:01, London 2026 in 2:16:16. And September 2026, Tokyo, the world title. She returned to the country where she had won the Olympics and won a world championship. Put it in one line: Olympic gold, world gold, four majors. Very few names in women's marathon history sit in that sentence. Sydney 2026 was meant to be the next line. The seventh major, its first edition as a major, and a margin of more than three minutes. The 2:18:31 is not her fastest — London's 2:16:16 is — but Sydney brought an unfamiliar course order and an August morning. Three minutes in a marathon is an era. Cheptai knew she was not racing a rival; she was chasing a performance. Now EPO, because most reporting says "drug" and leaves the reader imagining a pill at the start line. Erythropoietin is a natural hormone made in the kidneys that stimulates the production of new red blood cells. The body makes it on its own, and it is made in greater quantity by people living at altitude — which is why athletes from the Ethiopian and Kenyan highlands naturally carry a higher red cell mass, and why this particular substance is so hard to police. Injected erythropoietin does what the natural hormone does, only more of it. Red cells rise, the blood carries more oxygen, and the muscle gets the supply that decides the last ten kilometres of 42. In a marathon that difference shows on the clock. The gap between 2:22 and 2:18 is usually not a difference in muscle; it is a difference in delivery. The technical point that matters is the window. EPO is detectable in urine or blood only for a short period. In urine it is identified by isoelectric focusing — the recombinant molecule carries a different sugar profile from the natural one, and that difference is what gets caught. The window is typically a matter of days, sometimes a few weeks depending on the compound, but not months. That is precisely why out-of-competition testing is the load-bearing wall of this sport: a sample taken on race day cannot catch what was stopped three weeks earlier. Which brings up something worth entering into the record. A urine test is a photograph. The athlete biological passport is a film — haemoglobin, reticulocyte percentage, the markers tracked across months. A scan is a photograph; a ledger is a film. Only one shows what happens next. What is public in this case is the photograph: one sample, one substance, one date. The film is not public, and until it is, I have one frame. The Athletics Integrity Unit is not an old institution. It was created around 2026-16, when the international federation was under pressure over allegations of covering up doping, and it was placed in Monaco deliberately, at arm's length from the federation's marketing department. Its job is unglamorous: build the testing pool, collect whereabouts, manage samples. When a result comes back adverse, the first step is a provisional suspension, and that step is mandatory — not an official's judgement call. Jepchirchir's sample was collected in Kenya, before the race, out of competition. Read that sentence as a routine detail and you miss the most unusual fact in the file. To see why, you have to open the Kenya file from 2026 onwards. I opened it in 2026, while I was auditing the medical files of 23 Indian track athletes at the Gold Coast Commonwealth Games and wondering how the same work was done elsewhere. What I found was that the Kenyan women's marathon was a series nobody had entered on one page. Rita Jeptoo, the Boston winner, tested positive for EPO in 2026 and the case ran for years. Jemima Sumgong, the Rio 2026 Olympic marathon champion, tested positive for EPO in 2026. Then Diana Kipyokei, the Boston 2026 winner; Titus Ekiru; Lawrence Cherono; and Rhonex Kipruto, the 10km world record holder, whose case rested on the biological passport. I do not write that list to point at a country. The argument inside Kenya is sharper than anything I could write, and Kenyan coaches and reporters make it in blunter language than mine. I write it because a rate emerges from it. Over a decade, across both sexes, the number of elite Kenyan distance runners facing these allegations is not one or two. When the same story arrives repeatedly from the same system, the question moves off the individual and onto the system, which is the lesson my 2026 ledger taught me. Eleven soft-tissue injuries in one season is not luck. It is a system speaking. In doping the sentence changes slightly: this many cases in a decade is not luck either — it is a testing system and a supply system both speaking. One hole in that system has a date on it. In 2026 the World Anti-Doping Agency declared Kenya's national anti-doping organisation non-compliant, with questions over the independence of sample collection and analysis. Reform followed, legislation followed, and the issue resurfaced in 2026-25. Through all of it, the weakest link remained the one that matters most: the sample taken out of competition, at home, in a training camp, where there is no stadium, no medal ceremony and no camera. So when I read that the sample was collected in Kenya, before the race, my conclusion is not that the system failed. It is that this time the system worked at the exact point where it usually does not. That is a dry, unwelcome, necessary fact, and it is the least reported fact of the case. In 2026, the year of empty stadiums, I audited the home training programmes of 63 Indian athletes and found 41 per cent had no access to a physiotherapist. That same year I screened bodies through a laptop and learned they lie less than press conferences. Part of that lesson was that remote monitoring only works if you demand two consecutive clean screens, not one. In anti-doping, that principle has a name: the biological passport. A single good reading proves nothing; the pattern does. Which raises the question I most want answered and cannot answer. If a direct EPO test came back positive, the substance was present when the sample was taken. The interesting question is not how it was caught — it was caught, and that is good news. The question is what the passport markers were saying in the months before. If they were flat, this is a testing triumph. If they were moving and a direct test still arrived first, that is a threshold problem, and that argument is bigger than any one athlete. Now the arithmetic of 2:18:31. I read a marathon time the way an accountant reads a book — splits, drift, and the pace of the last ten kilometres. Sydney is not a flat course; it has the harbour sections and some rise, and an August morning starts humid. 2:18:31 is roughly 3:17 per kilometre. A three-minute margin means the runner in second had to find four to five seconds per kilometre, for 42 kilometres, continuously. That is not tactics. That is capacity. I dwell on this because it is where doping arguments turn sentimental — one camp says the performance is the proof, the other says the performance proves nothing. Both are wrong. The performance is not proof, but it is a document: it records what a body could do that morning. When a sample taken four weeks earlier tells a different story, the gap between two documents becomes the subject, not either document alone. Now the part without which this piece is incomplete, and which I have deliberately left for last. In the coming days you will read one word repeatedly: unfortunate. An unfortunate day for Kenya, an unfortunate episode for the marathon. I will not use it, because that word appears precisely where the record says something else. This case, at this stage, is a date, a sample and a rule. There is no room in it for misfortune. What exists is a sample collected in Kenya, a process that ran, and a provisional suspension that followed. When the hearing comes, the facts will be named, and so will the people responsible for them. The second thing being mangled is the status of the win. The Sydney title has not been taken from anyone. A provisional suspension does not annul a result; that is a separate process, and it begins only once the case is decided. But what happens in between never makes the papers: prize money held, ranking questioned, series points suspended, and above all, the first champion of the seventh major now permanently recorded with a date attached that everyone will read later. The third thing is my own irritation. The athlete with the most sponsors is the first to fall silent. The statements that follow a provisional suspension are not the athlete's words; they are a lawyer's, and in a lawyer's language you never write "I am innocent", you write "I respect the process". That is legally correct and humanly empty. In a sport where a living is made by selling a personality, a positive test gags the athlete before it punishes her. So when you see silence from Jepchirchir over the next months, do not assume she has nothing to say. Assume the permission to say it sits with someone else. The fourth point is my strongest objection. This case will be sold as a story about clean sport. The truth is that the cleanliness system is deeply uneven. A Kenyan marathoner is tested several times a year because she is in the pool and her name is large. The woman who finishes third in the same race may be tested once. That is not an argument that the rules are rigged against anyone; it is an observation that surveillance density tracks name value, and when density varies, so does the probability of being caught. Whoever was caught may well be guilty. It is not evidence that whoever was not caught is clean. The fifth point is the one that makes my own profession uncomfortable. I see in this case the same logic I have spent years documenting in injuries — the arithmetic of rushing back. An injured athlete returns early because a job, a quota, an instalment is at stake. In doping the argument is identical, only the paperwork differs: to win three more majors and an Olympics inside four years, a body has to be pushed at a rate that natural recovery does not permit. That is not an excuse; it is a physiological argument, and it is the argument the sport has never been willing to hear. I have written for thirty years that in Indian athletics an injury is an employment story the beat never reports as one. In Kenyan marathoning, doping is that same story — an economic story filed as a moral one. So I do what I do in every case. Nobody dated the first warning, so I did. Here the first warning was not a medical file; it was a calendar. Sapporo 2026, Boston 2026, London 2026, Tokyo 2026, Sydney 2026 — five peaks in five years, with three half marathon records folded in between. That sequence is not unusual in the modern marathon; it is the new normal, and that is the loudest signal in the file. Build a life on a calendar with a major every year and an Olympics every four, and the body has no window to repair itself. When there is no window, the demand for support rises. That support can be nutritional or prohibited. The athlete makes that call, and therefore carries the responsibility. But she did not draw up the calendar. Let me be exact about what I am not saying. I am not saying the system forced her to dope. An adult athlete owns her decisions, and if the allegations are proven, a sanction should follow. I am saying that if we never look at the hands that draw the calendar, we only ever see the hand holding the syringe. When bans fell on some members of the Delhi relay squad in 2026, I wrote the same thing: the question was not what they took, but who told them what to take. I am quoting what was documented at the time; what the CAS awards later established I attribute to the awards, not to my foresight. Now the forward ledger. There are three procedural paths. The B sample: if it also returns adverse, the case moves to a hearing. If it does not, or if the process is shown to be flawed, the provisional suspension can be lifted and she could line up at her next major. If the case is proven, the argument turns on when the sanction starts — the sample date or the suspension date — and that is exactly where the Sydney title, its prize money and its points sit. This is not new in marathon history. In 2026 the Rio women's marathon title stayed with its winner while her career did not; in 2026 a Boston winner's name acquired a date beside it. Both are already on the page. The bigger question for me is not the length of any ban. It is whether we change how we read 42 kilometres. Right now we read a marathon record as a statement about the body's limit — this is how far a human can go. If cases like this keep arriving, the record will start to mean something else: not the limit of the body, but the limit of the surveillance. And on that day, any time at all, 2:18:31 included, stops being someone's victory and becomes someone's test. I do not want that day. But if it is coming, I want a ledger waiting for it — with dates in it, not memories.